LifeScience Antibody Drug Conjugates
Astellas Pharma Gains NMPA Approval for PADCEV™ in China to Treat Advanced Urothelial Cancer
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that the Center for Drug Evaluation (CDE) of C...
August 20, 2024 | News
Mabwell's Nectin-4 Targeting ADC Receives Breakthrough Therapy Designation in China for Urothelial Carcinoma
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...
August 13, 2024 | News
Sanyou Bio and Huadong Medicine Advance SYHD001 ADC Drug to Phase I Clinical Trials
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration wi...
July 17, 2024 | News
Most Read
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- Ravindra Rao Joins GOBI Technologies as Director of Life Sciences – APAC
- Amgen Announces $900 Million Expansion of Ohio Biomanufacturing Facility, Boosting Investment to Over $1.4 Billion
- Thermo Fisher Scientific Appoints Former CVS Health CEO Karen S. Lynch to Board of Directors
- Merck KGaA Reshapes Leadership for the Future with Key Executive Moves
- Aarian Health Appoints Thomas Keller as Business Director to Drive Innovation and Growth
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
News
Editor Picks
